ISPE Biopharma

ATMP Manufacturing Protocols at ISPE Biopharmaceutical Manufacturing Conference!

May 28, 2020

Peter Walters and JP Bornholdt are presenting “ATMP Drug Products: Training for the Marathon” at the ISPE Biopharmaceutical Manufacturing Virtual Conference!

Join Peter Walters and JP Bornholdt, ATMP SMEs from CRB, on Tuesday, June 2nd at 12:30 pm EST, as they discuss the importance of establishing proper manufacturing protocols early in the development phase and why this is crucial to the long term goal of getting ATMP therapies to patients as quickly as possible.

Modeling multiple variations of a typical gene-modified cell therapy facility, CRB shows how early development efforts can directly affect your clinical and commercial facility design, cost and execution.

A number of challenges remain in the manufacture of these therapies, especially as we look to move to commercial-scale production. These challenges have caused industry participants to express concerns that the manufacturing shortage would threaten industry growth and lengthen time-to-market for these living therapies. While the industry is hyper-focused on racing to the finish line as fast as possible, we should consider the criticality of long term needs and how future-proofing manufacturing facilities by establishing proper manufacturing protocols in the development phase is crucial to getting ATMP therapies to patients.

To register for this event, click here. 
Tuesday, June 2nd
12:30 pm EST

Related Content

ATMP Manufacturing

Three strategies for successful ATMP facility design

Three essential strategies, from the earliest planning stages through your project’s maturity, will help position your ATMP facility for success.

Read More
multi-modal ATMP

Multimodal ATMP facilities to satisfy growing demand

Multi-modal ATMP facilities to satisfy growing demand Tuesday, April 28th at 12 pm EST Charles Heffernan and Emily Thompson This webinar will focus on how to deliver multi-product Advanced Therapy Medicinal Product (ATMP) facilities to adapt to an evolving product pipeline. Between newly developed products, strategic partnerships, and acquisitions in the ATMP market, companies are racing to find or create capacity for viral

Read More